These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 26587696)

  • 41. Technology-Based Educational Approaches to Address Opioid Use Management by Advanced Practice Registered Nurses.
    Kameg BN; Mitchell A
    Issues Ment Health Nurs; 2020 Oct; 41(10):940-945. PubMed ID: 32584628
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Buprenorphine: effective treatment of opioid addiction starts in the office.
    Fiellin DA
    Am Fam Physician; 2006 May; 73(9):1513-4. PubMed ID: 16719242
    [No Abstract]   [Full Text] [Related]  

  • 43. Practice Guidance for Buprenorphine for the Treatment of Opioid Use Disorders: Results of an Expert Panel Process.
    Farmer CM; Lindsay D; Williams J; Ayers A; Schuster J; Cilia A; Flaherty MT; Mandell T; Gordon AJ; Stein BD
    Subst Abus; 2015; 36(2):209-16. PubMed ID: 25844527
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Psychiatric Comorbidity and Substance Use Outcomes in an Office-Based Buprenorphine Program Six Months Following Hurricane Sandy.
    Tofighi B; Grossman E; Goldfeld KS; Williams AR; Rotrosen J; Lee JD
    Subst Use Misuse; 2015; 50(12):1571-8. PubMed ID: 26623697
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Use and misuse of opioid replacement therapies: a Queensland study.
    Smirnov A; Kemp R
    Subst Use Misuse; 2012 Jan; 47(1):78-85. PubMed ID: 22216993
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Things We Do for No Reason™: Discontinuing Buprenorphine When Treating Acute Pain.
    Haber LA; DeFries T; Martin M
    J Hosp Med; 2019 Oct; 14(10):633-635. PubMed ID: 31433765
    [No Abstract]   [Full Text] [Related]  

  • 47. No end to the crisis without an end to the waiver.
    Frank JW; Wakeman SE; Gordon AJ
    Subst Abus; 2018; 39(3):263-265. PubMed ID: 30676296
    [No Abstract]   [Full Text] [Related]  

  • 48. Trends in Buprenorphine Initiation and Retention in the United States, 2016-2022.
    Chua KP; Nguyen TD; Zhang J; Conti RM; Lagisetty P; Bohnert AS
    JAMA; 2023 Apr; 329(16):1402-1404. PubMed ID: 37097363
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Requiring Buprenorphine Waivers for Psychiatry Residents.
    Morris NP; Bentzley BS
    Acad Psychiatry; 2019 Feb; 43(1):131-134. PubMed ID: 30414072
    [No Abstract]   [Full Text] [Related]  

  • 50. To Stop or Not, That Is the Question: Acute Pain Management for the Patient on Chronic Buprenorphine.
    Anderson TA; Quaye ANA; Ward EN; Wilens TE; Hilliard PE; Brummett CM
    Anesthesiology; 2017 Jun; 126(6):1180-1186. PubMed ID: 28511196
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Buprenorphine and methadone for opioid addiction during pregnancy.
    Mozurkewich EL; Rayburn WF
    Obstet Gynecol Clin North Am; 2014 Jun; 41(2):241-53. PubMed ID: 24845488
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Managing opioid addiction with buprenorphine.
    Donaher PA; Welsh C
    Am Fam Physician; 2006 May; 73(9):1573-8. PubMed ID: 16719249
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Training rural practitioners to use buprenorphine; using The Change Book to facilitate technology transfer.
    McCarty D; Rieckmann T; Green C; Gallon S; Knudsen J
    J Subst Abuse Treat; 2004 Apr; 26(3):203-8. PubMed ID: 15063914
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Predictors of outcome in LAAM, buprenorphine, and methadone treatment for opioid dependence.
    Marsch LA; Stephens MA; Mudric T; Strain EC; Bigelow GE; Johnson RE
    Exp Clin Psychopharmacol; 2005 Nov; 13(4):293-302. PubMed ID: 16366759
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Buprenorphine/naloxone versus methadone in opioid dependence: a longitudinal survey.
    Curcio F; Franco T; Topa M; Baldassarre C;
    Eur Rev Med Pharmacol Sci; 2011 Aug; 15(8):871-4. PubMed ID: 21845796
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Commentary on Jin et al. (2020): Expanding the impact of opioid agonist therapy for opioid use disorder-are there lessons from the HIV/AIDS response?
    Klimas J; Wood E; McCracken R
    Addiction; 2021 Feb; 116(2):429-430. PubMed ID: 33037840
    [No Abstract]   [Full Text] [Related]  

  • 57. [Better efficacy of buprenorphine and methadone in opioid dependence. Requirements for abstinence from non-opioids before starting treatment paid off].
    Hoffmann O; Frisell F; Ljungberg T
    Lakartidningen; 2014 Jan 29-Feb 4; 111(5):147-9. PubMed ID: 24624763
    [No Abstract]   [Full Text] [Related]  

  • 58. Medicines and the drug control treaties: is buprenorphine for opioid addiction at risk of being lost?
    Costa E Silva JA
    Hum Psychopharmacol; 2004 Jun; 19(4):215-24. PubMed ID: 15181649
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Buprenorphine Deregulation and Mainstreaming Treatment for Opioid Use Disorder: X the X Waiver.
    Fiscella K; Wakeman SE; Beletsky L
    JAMA Psychiatry; 2019 Mar; 76(3):229-230. PubMed ID: 30586140
    [No Abstract]   [Full Text] [Related]  

  • 60. Factors associated with Medicaid patients' access to buprenorphine treatment.
    Baxter JD; Clark RE; Samnaliev M; Leung GY; Hashemi L
    J Subst Abuse Treat; 2011 Jul; 41(1):88-96. PubMed ID: 21459544
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.